Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 67.7% of People Wish to See Reform of Social Insurance Programs: Public Opinion Poll
September 20, 2004
- Public Course to Be Started to Train Experts on Life Ethics: Univ. of Tokyo
September 20, 2004
- Applications for Hospitals Run by Stock Companies to Be Received from Oct
September 20, 2004
- BUSINESS NEWS IN BRIEF
September 20, 2004
- Daiichi to Carry Out Organizational Reforms
September 20, 2004
- Fukujin, Seiwa Sangyo Form Business Alliance
September 20, 2004
- Bushu Pharmaceuticals Expanding Contract Manufacturing System
September 20, 2004
- Chugai to Establish Clinical Development Subsidiary
September 20, 2004
- Norvasc Ranks Top in 1st Half of 2004: IMS Data
September 20, 2004
- BI Reinforcing Independent Marketing System, Particularly in US: Dr Banchi
September 20, 2004
- Human ES Cells to Reduce Cost, Risk of Clinical Trials: PMSRL Seminar
September 20, 2004
- J&J to Strengthen Collaboration between 6 Subsidiaries in Japan: Mr Perkins
September 20, 2004
- BULLETIN
September 20, 2004
- MONITOR
September 20, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 20, 2004
- Health Science Research Group Surveying State of IRBs in Japan
September 20, 2004
- OTC NEWS IN BRIEF
September 20, 2004
- Switching to Olanzapine Monotherapy Improves QOL: Eli Lilly Japan
September 20, 2004
- NEW PRODUCTS
September 20, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…